Animal models are integral to the understanding of the pathophysiology of Alzheimer's disease and the development of novel therapies to prevent, reverse or delay disease progression. The same scientific rigor that is applied to human clinical trials should be applied to animal studies to ensure reliable and translatable preclinical data. To this end, Charles River and the Alzheimer's Drug Discovery Foundation (ADDF) convened a panel of experts to identify best practices for animal studies testing novel Alzheimer's disease therapies. The panel recommendations were published as Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies.